Most Read

Roche has received Japan’s Ministry of Health, Labour and Welfare (MHLW) approval for its Ronapreve to treat mild to moderate Covid-19 patients. Designed to block SARS-CoV-2 infectivity, Ronapreve

Private equity firm Partners Group has agreed to acquire Pharmathen from an international investment firm BC Partners in a deal valued about $1.88bn (€1.6bn). Private pharma company, Pharmathen

GlaxoSmithKline (GSK) has announced plans to construct a new campus for biotechnology and early-stage life science companies in Stevenage, England. The company is looking for a development partner

Regeneron has announced plans to invest about $1.8bn to expand its facilities at its Westchester County campus in the US, over the next six years. The company intends

Eli Lilly and Company is set to acquire the remaining shares of biotech firm Protomer Technologies in a deal valued more than $1bn. The latest move follows Lilly’s

Biotechnology company Prime Medicine has launched with $315m funding to advance its Prime Editing platform, a next-generation gene editing technology. The financing includes a $115m in series A

The Russian Direct Investment Fund (RDIF) has collaborated with Serum Institute of India (SII) to produce Sputnik V Covid-19 vaccine in India. RDIF and SII plan to produce

Danish pharma company Novo Nordisk has agreed to acquire Prothena’s clinical stage antibody PRX004 and broader ATTR amyloidosis programme for a deal valued at $1.2bn. Under the terms

Philip Morris International (PMI) has agreed to acquire British pharmaceutical firm Vectura Group for about $1.183bn (£852m) to expand its product pipeline development capabilities in inhaled therapeutics. The